$Relay Therapeutics (RLAY.US)$ Relay Therapeutics inc. repor...
$Relay Therapeutics(RLAY.US$ Relay Therapeutics inc. reported the first clinical results of its candidate FGFR2 inhibitor, RLY-4008, Oct. 8, saying it showed "promising early activity" in patients with cholangiocarcinoma FGFR2 fusion, unhindered by the toxicity issues typically associated with FGFR-class drugs.
The study plans to enroll 125 patients with various unresectable or metastatic solid tumors and is evaluating several dose levels of RLY-4008 once or twice a day. As of the September 9 cut-off date for the interim analysis, 48 of 49 participants had primary FGFR2 alterations, the majority of which were fgFR2-fused cholangiocarcinomas.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
